34520759|t|The AKT modulator A-443654 reduces alpha-synuclein expression and normalizes ER stress and autophagy.
34520759|a|Accumulation of alpha-synuclein is a main underlying pathological feature of Parkinson's disease and alpha-synucleinopathies, for which lowering expression of the alpha-synuclein gene (SNCA) is a potential therapeutic avenue. Using a cell-based luciferase reporter of SNCA expression we performed a quantitative high-throughput screen of 155,885 compounds and identified A-443654, an inhibitor of the multiple functional kinase AKT, as a potent inhibitor of SNCA. HEK-293 cells with CAG repeat expanded ATXN2 (ATXN2-Q58 cells) have increased levels of alpha-synuclein. We found that A-443654 normalized levels of both SNCA mRNA and alpha-synuclein monomers and oligomers in ATXN2-Q58 cells. A-443654 also normalized levels of alpha-synuclein in fibroblasts and iPSC-derived dopaminergic neurons from a patient carrying a triplication of the SNCA gene. Analysis of autophagy and endoplasmic reticulum stress markers showed that A-443654 successfully prevented alpha-synuclein toxicity and restored cell function in ATXN2-Q58 cells, normalizing the levels of mTOR, LC3-II, p62, STAU1, BiP, and CHOP. A-443654 also decreased the expression of DCLK1, an inhibitor of alpha-synuclein lysosomal degradation. Our study identifies A-443654 and AKT inhibition as a potential strategy for reducing SNCA expression and treating Parkinson's disease pathology.
34520759	4	7	AKT	Gene	207
34520759	18	26	A-443654	Chemical	MESH:C504035
34520759	35	50	alpha-synuclein	Gene	6622
34520759	118	133	alpha-synuclein	Gene	6622
34520759	179	198	Parkinson's disease	Disease	MESH:D010300
34520759	203	226	alpha-synucleinopathies	Disease	MESH:D000080874
34520759	265	280	alpha-synuclein	Gene	6622
34520759	287	291	SNCA	Gene	6622
34520759	370	374	SNCA	Gene	6622
34520759	473	481	A-443654	Chemical	MESH:C504035
34520759	530	533	AKT	Gene	207
34520759	560	564	SNCA	Gene	6622
34520759	566	573	HEK-293	CellLine	CVCL:0045
34520759	605	610	ATXN2	Gene	6311
34520759	612	621	ATXN2-Q58	CellLine	CVCL:SE31
34520759	654	669	alpha-synuclein	Gene	6622
34520759	685	693	A-443654	Chemical	MESH:C504035
34520759	720	724	SNCA	Gene	6622
34520759	734	749	alpha-synuclein	Gene	6622
34520759	776	785	ATXN2-Q58	CellLine	CVCL:SE31
34520759	793	801	A-443654	Chemical	MESH:C504035
34520759	828	843	alpha-synuclein	Gene	6622
34520759	904	911	patient	Species	9606
34520759	943	947	SNCA	Gene	6622
34520759	1029	1037	A-443654	Chemical	MESH:C504035
34520759	1061	1076	alpha-synuclein	Gene	6622
34520759	1077	1085	toxicity	Disease	MESH:D064420
34520759	1116	1125	ATXN2-Q58	CellLine	CVCL:SE31
34520759	1159	1163	mTOR	Gene	2475
34520759	1165	1168	LC3	Gene	84557
34520759	1173	1176	p62	Gene	23636
34520759	1178	1183	STAU1	Gene	6780
34520759	1185	1188	BiP	Gene	2662
34520759	1194	1198	CHOP	Gene	1649
34520759	1200	1208	A-443654	Chemical	MESH:C504035
34520759	1242	1247	DCLK1	Gene	9201
34520759	1265	1280	alpha-synuclein	Gene	6622
34520759	1338	1341	AKT	Gene	207
34520759	1390	1394	SNCA	Gene	6622
34520759	1419	1438	Parkinson's disease	Disease	MESH:D010300
34520759	Association	MESH:D010300	207
34520759	Association	MESH:D000080874	6622
34520759	Negative_Correlation	MESH:C504035	MESH:D064420
34520759	Association	MESH:C504035	6780
34520759	Association	MESH:C504035	1649
34520759	Association	MESH:D010300	6622
34520759	Negative_Correlation	6622	9201
34520759	Association	6311	6622
34520759	Negative_Correlation	MESH:C504035	9201
34520759	Negative_Correlation	MESH:C504035	207
34520759	Association	MESH:C504035	84557
34520759	Association	MESH:C504035	2475
34520759	Association	207	6622
34520759	Negative_Correlation	MESH:C504035	6622
34520759	Association	MESH:C504035	23636
34520759	Association	MESH:C504035	2662

